25 completed, 3 terminated, 2 active not recruiting, 2 unknown. 15 Phase 3, 9 Phase 2, 6 Phase 4, 2 Early Phase 1, 1 Not applicable.
Follow elagolix: new trials by email Literature Review of elagolix trials Research Report on elagolix
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain Elagolix, Oral Contraceptive (OC) - Endometriosis (Diagnosis) | Phase 4 | Enrolling by invitation | Pak Emirates Military Hospital | 90 | 2026-05-01 | 2026-04-16 |
| Effect of Elagolix in Symptomatic Endometrioma in Comparison to Combined Oral Contraceptive Pill. tab Elagolix 150mg, Combined oral contraceptive pill (ethinyl estradiol,30mcg+desogestrel,150mcg) tablet - Endometrioma | Not applicable | Completed | Mst.Sumyara Khatun | 60 | 2025-04-17 | 2026-08-13 |
| Role of Menopause in Thermoregulation Elagolix Oral Tablet, Estradiol patch, cellulose placebo - Menopause, Aging | Phase 4 | Recruiting | Penn State University | 24 | 2025-03-01 | 2026-10-02 |
| Brain Blood Flow Responses to Stress: Sex Differences Indomethacin, Placebo, Orilissa - Cerebrovascular Disorders | Phase 4 | Completed | University of Wisconsin, Madison | 22 | 2024-07-24 | 2026-09-24 |
| Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp Elagolix 200 MG, Placebo or SOC IVF - Infertility, Endometriosis | Phase 3 | Active not recruiting | Yale University | 97 | 2024-03-16 | 2026-06-05 |
| A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated Pain Elagolix, Elagolix placebo - Endometriosis | Phase 3 | Completed | Nanjing Chia-tai Tianqing Pharmaceutical | 202 | 2023-09-14 | 2025-09-23 |
| A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated Pain Elagolix, Elagolix placebo - Endometriosis | Phase 3 | Unknown | Qilu Pharmaceutical (Hainan) Co., Ltd. | 336 | 2022-09-04 | 2022-12-13 |
| Cardiovascular Disease Risk in Women With Endometriosis Elagolix - Endometriosis | Early Phase 1 | Completed | Yale University | 21 | 2022-07-01 | 2026-10-16 |
| Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis Elagolix 200 MG, Placebo or SOC IVF - Infertility, Endometriosis | Phase 3 | Completed | Yale University | 103 | 2022-03-15 | 2026-06-12 |
| Elagolix for Fertility Enhancement Clinical Trial Elagolix, Ortho Cyclen - Endometriosis, Unexplained Infertility | Phase 2 | Completed | Wake Forest University Health Sciences | 10 | 2022-01-15 | 2024-07-26 |
| An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal Women Elagolix - Mild Autonomous Cortisol Excess | Phase 4 | Terminated | Icahn School of Medicine at Mount Sinai | 4 | 2021-07-06 | 2025-03-18 |
| Study to Gather Information How Well Three Different Doses of BAY1817080 Given Twice Daily Over 12 Weeks Work in Comparison to an Inactive Pill (Placebo) and Elagolix in Women Suffering From Pain Related to a Condition Where the Tissue That Usually Grows Inside the Womb Grows Outside of the Womb BAY1817080, Elagolix, Placebo - Endometriosis | Phase 2 | Terminated | Bayer | 215 | 2021-01-29 | 2023-08-01 |
| Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With Endometriosis Elagolix 200 MG, Leuprolide Acetate 3.75 MG/ML, Lab work - Infertility, Endometriosis | Early Phase 1 | Completed | Colorado Center for Reproductive Medicine | 30 | 2020-09-01 | 2025-02-20 |
| Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain Elagolix, Placebo, Combined Oral Contraceptive - Endometriosis | Phase 3 | Active not recruiting | AbbVie | 800 | 2020-08-10 | 2026-06-12 |
| Hormonal Effects of the Oral Gonadotropin Releasing Hormone (GnRH) Antagonist at Different Periods of the Menstrual Cycle Elagolix 200 MG Oral Tablet [Orilissa] - Ovulation; Failure or Lack of | Phase 4 | Unknown | University of Southern California | 12 | 2019-10-01 | 2019-08-19 |
| Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome Elagolix, Placebo - Polycystic Ovary Syndrome | Phase 2 | Completed | AbbVie | 118 | 2019-08-12 | 2022-06-08 |
| A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Elagolix, Placebo - Uterine Fibroids | Phase 4 | Completed | AbbVie | 82 | 2019-04-12 | 2022-03-31 |
| A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain elagolix, estradiol/norethindrone acetate (E2/NETA) - Endometriosis | Phase 3 | Terminated | AbbVie | 11 | 2017-12-27 | 2019-11-27 |
| Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo - Heavy Menstrual Bleeding, Uterine Fibroids | Phase 3 | Completed | AbbVie | 478 | 2017-09-13 | 2025-07-22 |
| A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain Estradiol/Norethindrone Acetate, Placebo for Elagolix, Elagolix - Endometriosis | Phase 3 | Completed | AbbVie | 681 | 2017-07-07 | 2024-12-20 |
Showing 20 of 34. Sign in to see all of them.
Endometriosis (22) · Dysmenorrhea (7) · Leiomyoma (7) · Menorrhagia (7) · Infertility (3) · Pain (2) · Anovulation (1) · Cerebrovascular Disorders (1) · Disease (1) · Dyspareunia (1) · Heat Stress Disorders (1) · Pelvic Pain (1) · Polycystic Ovary Syndrome (1)
AbbVie (17) · AbbVie (prior sponsor, Abbott) (3) · Yale University (3) · Bayer (1) · Colorado Center for Reproductive Medicine (1) · Icahn School of Medicine at Mount Sinai (1) · Mst.Sumyara Khatun (1) · Nanjing Chia-tai Tianqing Pharmaceutical (1) · Pak Emirates Military Hospital (1) · Penn State University (1) · Qilu Pharmaceutical (Hainan) Co., Ltd. (1) · University of Southern California (1) · University of Wisconsin, Madison (1) · Wake Forest University Health Sciences (1)
United States (19) · Puerto Rico (8) · Canada (5) · China (3) · Austria (1) · Bangladesh (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · Estonia (1) · Finland (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1)
Emily Jungheim, MD (2) · Heping Zhang, PhD (2) · Hugh Taylor, MD (2) · Nanette Santoro, MD (2) · Steven Young, MD, PhD (2) · Abisola Tepede, PharmD (1) · Alice C Levine (1) · Bruce A Lessey, MD, PhD (1) · Charlotte Owens, MD (1) · David Weinberg, PhD (1) · Eric Surrey, MD (1) · Jim Segars, MD (1) · Kristof Chwalisz, MD, PhD, MD (1)
PMID 34878624, PMID 29476499, PMID 28525302, PMID 32621325, PMID 32945631, PMID 33650259, PMID 33963686, PMID 31654294, PMID 30724096, PMID 30992150, PMID 31227284, PMID 31971678, PMID 32769633, PMID 33066973, PMID 33564263, PMID 34134684, PMID 34553161, PMID 34582715, PMID 39381651, PMID 11163814, PMID 11726570, PMID 12372443, PMID 2005218, PMID 22500852, PMID 25395741, PMID 27733082, PMID 28323948, PMID 29889764, PMID 30303923, PMID 30383729, PMID 31069056, PMID 31650182, PMID 32702363, PMID 34363198, PMID 34435897, PMID 34553156, PMID 34978027, PMID 3543765, PMID 35715184, PMID 37398623, PMID 37769311, PMID 38890641
R01HD100336 (1), R01HL150361 (1), R01HL161000 (1)